MVP Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MVPT research report →
Price Chart
About the company
Based in Fresno, California, MVP Holdings Inc. operates across a diverse range of sectors. The company's activities encompass real estate, consumer products and services, and web-based solutions.
- CEO
- Casey Musick
- IPO
- 2006
- Employees
- 35
- HQ
- Fresno, CA, US
Get TickerSpark's AI analysis on MVPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $56
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.96
- Div Yield
- 0.00%
- Gross Margin
- 68.19%
- Op Margin
- -80.77%
- Net Margin
- -81.88%
- ROE
- 318.94%
- ROIC
- -44.53%
Latest fiscal year · YoY change
- Revenue
- $527.19K-92.9%
- Gross Profit
- $359.51K-73.9%
- Op Income
- $-425,801
- Net Income
- $-431,677-22.0%
- EPS
- $-0.43-2.4%
- OCF Growth
- -518.7%
- FCF Growth
- -659.6%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 8.85
- RSI (14)
- 48
- Avg Volume
- 3
No earnings-call transcripts are available for MVPT yet.
- Free Float
- 9.1%
- Shares Outstanding
- 557.90K
- Float Shares
- 50.58K
Our MVPT coverage
Recent articles, reports, and earnings notes.
No research on MVPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MVPT report →New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
prnewswire.com · Aug 3
Napco Security: How The MVP Platform Secures Napco's Future
seekingalpha.com · Jul 21
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
thenewswire.com · May 1
First Horizon Recognized with a 2026 Training MVP Award by Training Magazine
prnewswire.com · Mar 11
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
thenewswire.com · Jan 29
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
newsfilecorp.com · Jan 20
Digitalage Announces MVP Launch for Live, Creator-First Media Platform
accessnewswire.com · Jan 2
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
newsfilecorp.com · Dec 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.